Open access peer-reviewed chapter - ONLINE FIRST

Ultrasound Based Elastography Techniques for the Evaluation of Nonalcoholic Liver Disease

Written By

Ioan Sporea, Raluca Lupușoru and Roxana Șirli

Submitted: December 3rd, 2021 Reviewed: December 22nd, 2021 Published: March 1st, 2022

DOI: 10.5772/intechopen.102363

Elastography - Applications in Clinical Medicine Edited by Dana Stoian

From the Edited Volume

Elastography - Applications in Clinical Medicine [Working Title]

Dr. Dana I Stoian and Dr. Alina Popescu

Chapter metrics overview

51 Chapter Downloads

View Full Metrics


The number of NAFLD patients is increasing in the developed world and non-invasive modalities for their evaluation are needed. Ultrasound-based methods are very useful for this approach, starting with standard ultrasound used for steatosis detection, and continuing with new modalities for steatosis, fibrosis, and inflammation quantification. Modern ultrasound systems can quantify all these parameters in NAFLD patients, thus making ultrasound a real Multiparameter Ultrasound (MPUS). The performance of ultrasound-based methods is very well documented with liver stiffness assessment as a marker of fibrosis, and more recently, for quantification of steatosis and viscoelastic properties as a marker of inflammation.


  • nonalcoholic fatty liver disease (NAFLD)
  • fatty liver
  • ultrasound
  • liver elastography
  • fat quantification

1. Introduction

Currently, at least in the developed world, the focus of hepatology changed, from chronic viral hepatitis (B or C), which is now well controlled with efficient drugs, to the problem of fatty liver. This disease occurs in both non-alcoholic patients with metabolic conditions as well as in alcoholic patients [1]. Nonalcoholic fatty liver disease (NAFLD) become more and more present in clinical practice, since it currently affects more than a quarter of the world population [2] and the prevalence is increasing [3]. Overweight and obesity, type 2 diabetes, dyslipidemia, and sedentariness are increasing at a global level, at least in the developed world [4, 5]. For a long time, the fatty liver was considered to be a “benign” entity, but in the last years, the potential evolution of this disease to severe fibrosis and cirrhosis has been proven. Furthermore, in the last years, NAFLD became an important indication for liver transplantation [6, 7, 8].

Recently, new terminology for NAFLD was proposed, to better reflect its clinical spectrum: Metabolic Associated Fatty Liver Disease (MAFLD) [9, 10]. This new terminology is used more and more, having the advantage to underline the role of metabolic factors and to not exclude the use of alcohol. Thus, we must be focused to screen for fatty liver in the population at risk: patients with obesity, metabolic syndrome, and type 2 diabetes mellitus (DM).

Recent data showed that 650 million people around the world are obese and 1,9 billion are overweight (39% of the adult population)! Type 2 diabetes mellitus (type 2 DM) become a frequent cause of morbidity in the last decade (1 in 11 people of the developed countries have type 2 DM) [11]. Furthermore, many of type 2 DM patients are overweight and obese. Association of obesity and type 2 DM increases the risk for fatty liver infiltration. Features of metabolic syndrome are frequent in the adult population; thus, all these conditions explain the increased incidence of fatty liver in daily practice.

These huge cohorts of patients should be evaluated, especially in regard to fibrosis severity, the main driver of fibrosis. Simple non-invasive biologic tests to predict significant fibrosis in patients with NAFLD are available, such as Fibrosis-4 (FIB-4) or APRI (which uses only transaminases serum levels, platelet count and age), with acceptable accuracy [12]. Other biologic tests are more accurate [Enhanced Liver Fibrosis (ELF™) Test, FibroMax, others], but also more complex and more expensive.

In the last 15 years numerous ultrasound (US) based elastography techniques have been developed [Transient Elastography (TE), point Shear Wave Elastography (pSWE) or 2D-SWE], which have demonstrated their practical value in many studies. International Guidelines classify these US elastography techniques into: Strain Elastography (used mostly for breast, thyroid and prostate nodules) and Shear Waves Elastography (SWE - in which external impulses generate shear waves inside the liver, whose speed is measured by ultrasound) [13, 14]. The faster the shear-waves speed are, the stiffer the tissue and the fibrosis are more severe. Based on the generation of the external impulse and the technology used to measure the shear-waves speed, SWE elastography is subdivided into: Transient Elastography (with a mechanic external impulse), Point SWE (pSWE) [in which an Acoustic Radiation Force Impulse (ARFI) is used and the shear-waves speed is measured in a point], and real-time elastography which includes 2D-SWE and 3D-SWE (in which ARFI is used, shear-waves speed is measured in an area of interest and in the same time a color-coded elastogram is generated) [13, 14].

However, in patients with NAFLD, not only the evaluation of fibrosis is important, but also quantification of steatosis and inflammation is of practical value.

In this chapter, we aim to discuss the ultrasound-based methods for the evaluation of patients with NAFLD. In such patient’s evaluation and quantification of steatosis, fibrosis and inflammation are important. In practice, these methods are frequently used and more and more data are collected regarding their value.


2. Steatosis evaluation

In patients with NAFLD, the presence of steatosis is a common fact and then the evaluation of its severity is necessary. Ultrasonography(US) is the simplest way to evaluate steatosis, and two signs are important: “bright” hyperechoic liver” with posterior attenuation (Figure 1) and increased hepato-renal index (Figure 2). Using these two signs, a semiquantitative assessment of steatosis severity can be performed. Many papers evaluated the performance of liver ultrasound for the assessment of the steatosis severity, some of them are quite old papers. Mathiesen et al. [15] compared the US with hepatic histology for steatosis assessment in a series of 165 patients. Steatosis was graded as none, mild, moderate or severe. In patients with increased echogenicity, 86.7% had at least moderate liver steatosis by histology. To detect steatosis, US had a sensitivity of 0.90, a specificity of 0.82, a positive predictive value of 0.87 and a negative predictive value of 0.87. In another study, Palmentieri et al. [16] compared the “bright liver” echo pattern to liver biopsy in 235 patients. The study showed that the “bright liver” echo pattern was found in 67% of patients with steatosis of any degree and in 89% of patients with severe steatosis (≥30% of the hepatocytes involved). Among the subgroup of patients who had severe steatosis, the sensitivity and specificity of US were 91% and 93%, respectively.

Figure 1.

“Bright liver” with posterior attenuation.

Figure 2.

Increased hepato-renal index.

Maybe the most important paper regarding the value of liver US for diagnosing fatty liver is a large meta-analysis [17], which included 49 studies and 4720 subjects. The sensitivity of US for moderate and severe steatosis was 84.8% (CI 95%: 79.5–88.9%), with a specificity of 93.6% (CI 95%: 87.2–97.0%).

Computer Assisted Diagnosis (CAD) was also evaluated as a tool to increase the accuracy of US for the detection and severity assessment of steatosis [18]. In a study including 120 patients [19], CAD was able to correctly classify the severity of steatosis with an accuracy of 82.2%. More recently, Artificial Intelligence (AI) has been used for the same purpose [20].

All these papers are in favor to use liver ultrasound for the detection of steatosis in patients with risk factors. The latest update of the European Association for the Study of the Liver (EASL) Guidelines regarding the non-invasive evaluation in chronic liver disease [12] states that: “Conventional ultrasound should be used as a first-line tool for the diagnosis of steatosis in clinical practice, despite its well-known limitations”. This method can be used for a semi-quantitative assessment of the severity of fatty infiltration.

For a quantitative evaluation of liver steatosis, the most used method in this moment is Controlled Attenuation Parameter (CAP). It is a module implemented on a FibroScan device (Echosens, Paris, France), which measures the attenuation of the ultrasound beams throughout the liver to assess steatosis severity. CAP was first used on the M probe and latter also on the XL probe (Figure 3).

Figure 3.

FibroScan (Echosens, Paris, France) with M and XL probes (in light blue CAP values are shown, while in yellow the liver stiffness values).

Many papers have been published on the value of CAP for liver steatosis assessment, comparing it to liver biopsy. In the next table, we resumed the main published papers concerning the value of CAP (Table 1).

StudyNo. of patientsCut-off values for each steatosis grade (dB/m)
S ≥ 1S ≥ 2S ≥ 3
Chan 2014 [21]105263281283
De Ledinghen 2016 [22]261310311
Imajo 2016 [23]142236279302
Park 2017 [24]104261305312
Naveau 2017 [25]123298303326
Sissiqui 2019 [26]393285311306
Shalimar 2020 [27]219285331348
Oeda 2019 [28]137264289
Eddowes 2019 [29]88302331337
Petroff 2021 [30]2346294310331
Karlas 2017 [31]2735248268280
Kamali 2019 [32]77237259291
Zenovia 2021 [33]204245273,5333
Mikolasevic 2021 [34]179304311345
Park 2017 [24]104261
Gu 2021 [35]1183/3295/2835273.5288.5309

Table 1.

Value of CAP for liver steatosis assessment.

Having in mind that the CAP module is available both in M and XL probes, the next question is if the same cut-off values can be used in practice for both probes? Chan et al. evaluated a cohort of 180 patients by liver biopsy and CAP with both M and XL probes [36]. The group had a mean age of 53.7 ± 10.8 years and NAFLD was identified in 86.7% of them, the sensitivity, specificity, PPV, and NPV of CAP using the M/XL probe for the diagnosis of steatosis grade ≥ S1 was 93.9%/93.3%, 58.8%/58.8%, 95.6%/95.6%, and 50.0%/47.6%, respectively. Thus, the authors concluded that the same cut-off values for CAP may be used for the M and XL probes for the diagnosis of hepatic steatosis grade.

However, in another prospective study on 100 adults [37], which compared CAP with the M vs. the XL probe for quantification of hepatic fat content, using magnetic resonance imaging proton density fat fraction (MRI-PDFF) as the standard, the mean CAP values by M probe (310 ± 62 db/m) were significantly lower than by the XL probe (317 ± 63 db/m) (P = 0.007). The authors demonstrated that the M probe under-quantifies CAP values as compared with the XL probe and they proposed that the type of probe should be considered when interpreting CAP data from patients with fatty liver.

In the last years, ultrasound modules for the quantification of liver steatosishave been implemented in standard US machines, by several companies. The advantage of these systems is that when steatosis is seen by standard ultrasound, immediately a quantification can be performed. Several papers have been published in this area, with good results. In the following pages, we will present the most recent developments in this field.

Ultrasound Guided Attenuation Parameter(UGAP) from General Electric (Figure 4) was evaluated for the detection of hepatic steatosis as compared with CAP, using histopathology as the reference standard [38]. In a cohort of 163 chronic liver disease patients who underwent UGAP, CAP and liver biopsy on the same day, the AUROC’s of UGAP for identifying >S1, >S2 and S3 were 0.900, 0.953 and 0.959, respectively, which were significantly better than the results obtained with CAP.

Figure 4.

UGAP (ultrasound-guided attenuation parameter).

Attenuation imaging (ATI)from Canon (Figure 5) has shown promising results for fatty quantification in several published papers. In a study performed on 114 subjects potentially at risk of steatosis and 15 healthy controls, ATI results were compared to the ones obtained with CAP, using MRI-PDFF as the reference method [39]. ATI showed a better correlation with MRI-PDFF (r = 0.81) than CAP (r = 0.65). Similar good results have been obtained by the same group in a later paper [39]. In this study, the correlation between ATI and PDFF was better than with CAP (0.83 vs. 0.58).

Figure 5.

Attenuation image from Canon.

In another study, in which liver histology was used as a reference in a series of 108 subjects, it has been reported that the degree of steatosis was the only significant determinant factor for the ATI results and that the AUROCs for different grades of steatosis ranged from 0.84 to 0.93 [40].

In a study that used once again MRI-PDFF as reference [41], in a cohort of 87 patients, the AUROCs of ATI for detection of hepatic steatosis ≥5% and ≥ 10%, were 0.76 and 0.88, respectively (95% CI: 0.66–0.85 and 0.79–0.94) and the correlation of ATI with MRI-PDFF was moderate (p = 0.66).

The Attenuation coefficient (ATT)from Hitachi was used in a multicenter prospective study including patients who underwent liver biopsy and ATT measurements on the same day [42]. Correlations between ATT and steatosis grade were evaluated. In a total of 351 patients that were enrolled in this study, the median values of ATT for steatosis grades S0, S1, S2, and S3 were 0.55, 0.63, 0.69, and 0.85 dB/cm/MHz, respectively, and ATT increased with the increase in steatosis grade (P < 0.001). The AUROC’s corresponding to S ≥ 1, S ≥ 2, and S ≥ 3 were 0.79, 0.87, and 0.96, respectively.

Speed of sound estimation (SSE)(Figure 6) implemented in the Aixplorer US system - MACH 30 was compared with MRI-PDFF in a pilot study including 100 patients [43]. The technique’s reproducibility was excellent, with an intraclass correlation coefficient (ICC) of 0.93. An SSE cutoff ≤1.537 mm/μs showed 80% sensitivity and 85.7% specificity in detecting any steatosis (S1–S3). In a multivariant regression analysis, only MRI-PDFF and BMI were associated with SSE values.

Figure 6.

Speed of sound estimation (SSE).

In another study in a cohort of 215 NAFLD patients using Aixplorer MACH 30 system [44] for the evaluation of steatosis, Sound Speed Plane-wave UltraSound (SSp.PLUS) and Attenuation Plane-wave UltraSound (Att.PLUS) were used in comparison with CAP. In this study, SSp.PLUS correlated better than Att.PLUS with CAP values: (r = −0.74 vs. r = 0.45) and the best SSp.PLUS cut-off value for predicting the presence significant steatosis by CAP was 1524 m/s.

Quantification of steatosis (AC-TAI and SC-TAI)using the Samsung ultrasound system (Figures 7 and 8) was evaluated in a cohort of 120 subjects suspected of having NAFLD [45]. The participants underwent US examination for radiofrequency (RF) data acquisition. Using RF data analysis, the attenuation coefficient (AC) based on tissue attenuation imaging (TAI) (AC-TAI) as well as a scatter-distribution coefficient (SC) based on tissue scatter-distribution imaging (TSI) (SC-TSI) were measured and compared with MRI-PDFF. In this study, AC-TAI and SC-TSI were significantly correlated with MRI-PDFF (r = 0.659 and 0.727, p < 0.001 for both). For detecting hepatic fat contents of ≥5% and ≥ 10%, the areas under the AUROCs of AC-TAI were 0.861 (95% CI: 0.786–0.918) and 0.835 (95% CI: 0.757–0.897), while those of SC-TSI were 0.964 (95% CI: 0.913–0.989) and 0.935 (95% CI: 0.875–0.972), respectively.

Figure 7.

AC-TAI- severe steatosis.

Figure 8.

AC-TSI severe steatosis.

All these results concerning the quantification of liver steatosis using ultrasound are very promising and every day new papers are published in well-known medical journals considering the rapid development of this field.


3. Evaluation of fibrosis

In the early times of non-invasive assessment of patients with chronic liver disease, the main field of research was liver fibrosis. Replacing in many cases liver biopsy, this assessment is essential for the prognosis of patients [46, 47]. Early papers in this field evaluated Transient Elastography (TE) as a predictor of fibrosis in NAFLD [48]. Later, ARFI technologies (Acustic Radiation Force Impulse) with pSWE and 2D-SWE became fields of research [49]. In Table 2 we presented the main papers evaluating TE and SWE methods for the assessment of liver fibrosis in NAFLD patients.

StudyNo of patientsElastographyCut-off values for each fibrosis stage
Petta 2016 [50]324TE>10.5 kPa>12.5 kPa
Yoneda 2007 [51]67TE>5.6 kPa>6.65 kPa>8 kPa>17 kPa
Gaia 2011 [52]72TE>5.5 kPa>7 kPa>8 kPa>10.5 kPa
Kumar 2013 [53]205TE>6.1 kPa>7 kPa>9 kPa>11.8 kPa
Lupsor 2010 [54]72TE>6.8 kPa>10.4 kPa
Petta 2011 [55]169TE>7.25 kPa>8.75 kPa
Ratziu 2010 [56]53TE>5.1 kPa>9.1 kPa>11.1 kPa>14.5 kPa
Yoneda 2008 [57]50TE>6.6 kPa>9.8 kPa>17.5 kPa
Nobili 2008 [58]52TE>7.4 kPa>10.2 kPa
Wong 2010 [48]146TE>7 kPa>8.7 kPa>10.3 kPa
Wong 2012 [59]193TE>6.2 kPa>7.2 kPa>7.9 kPa
Musso 2011 [60]60TE>7 kPa>8.7 kPa
Yoneda 2010 [61]54TE>9.9 kPa>16 kPa
Mahadeva 2013 [62]131TE>6.65 kPa>7.1 kPa>10.6 kPa
Imajo 2016 [23]152TE>11 kPa>11.4 kPa>14 kPa
Pathik 2015 [63]89TE>9.1 kPa>12 kPa>20 kPa
Kumar 2013 [53]207TE>7 kPa>9 kPa>11.8 kPa
Cassinotto 2016 [49]291TE>6.2 kPa>8.2 kPa>9.5 kPa
Kamali 2019 [32]77TE>8 kPa>11 kPa>16 kPa
Eddowes 2019 [29]88TE>8.2 kPa>9.7 kPa>13.6 kPa
Park 2017 [24]104TE>6.10 kPa
Seki 2017 [64]171TE>7.2 kPa>10.0 kPa
Lee 2017 [65]94TE>7.4 kPa> 8 kPa>10.8 kPa
Hsu 2018 [66]230TE>6.2 kPa>7.6 kPa>8.8 kPa>11.8 kPa
Attia 2016 [67]61TE>7.0 kPa>11.8 kPa>15.0 kPa
Myers 2010 [68]50TE>10.3 kPa>11.1 kPa
Myers 2012 [69]276TE>16 kPa
Furlan 2020 [70]59TE>8.8 kPa>6.7 kPa
Leong 2020 [71]100TE>7.68 kPa>9.13 kPa>9.28 kPa>13.4 kPa
Imajo 2020 [72]221TE>6.95 kPa>8.14 kPa>13.8 kPa>19.5 kPa
Yoneda 2010 [61]54pSWE>1.77 m/s>1.9 m/s
Fierbinteanu 2013 [73]64pSWE>1.48 m/s>1.63 m/s
Cassinotto 2013 [74]165pSWE>1.3 m/s>1.51 m/s>1.61 m/s
Friedrich-Rust 2012 [75]50pSWE>1.37 m/s
Osaki 2010 [76]101pSWE>1.34 m/s>1.79 m/s>2.2 m/s>2.9 m/s
Lee 2017 [65]94pSWE>1.35 m/s>1.43 m/s>1.50 m/s
Attia 2016 [66]61pSWE>1.18 m.s>1.45 m/s>1.95 m/s
Palmeri 2011 [77]172pSWE>1.49 m/s
Cui 2016 [78]114pSWE>1.29 m/s>1.34 m/s>2.48 m/s
Li 2016 [79]136pSWE>1.30 m/s>1.36 m/s>1.41 m/s
Leong 2020 [72]100pSWE>6.83 kPa>6.98 kPa>7.02 kPa>11.5 kPa
Sharpton 2021 [80]114pSWE>7.8 kPa>6.8 kPa>8.7 kPa>10.6 kPa
Cassinotto 2016 [49]2912D-SWE>6.3 kPa>8.3 kPa>10.5 kPa
Herrmann 2017 [81]1562D-SWE>7.1 kPa>9.2 kPa>13 kPa
Takeuchi 2018 [82]712D-SWE>6.6 kPa>11.6 kPa>13.1 kPa>15.7 kPa
Jamialahmadi 2019 [83]902D-SWE>5.6 kPa>6.6 kPa>6.8 kPa>6.8 kPa
Lee 2017 [65]942D-SWE>8.3 kPa>10.7 kPa>15.1 kPa
Furlan 2020 [70]572D-SWE>5.7 kPa>8.1 kPa
Sharpton 2021 [80]1142D-SWE>7.5 kPa>7.7 kPa>7.7 kPa>9.3 kPa
Imajo 2020 [72]2212D-SWE>6.65 kPa>8.04 kPa>10.6 kPa>12.37 kPa

Table 2.

Value of TE, pSWE and 2D-SWE for liver fibrosis assessment in NAFLD patients.

Considering the practical value of different systems, TE is the oldest system, a semi-blind method of evaluation, it can assess fibrosis severity as well as steatosis (with CAP) in the same machine, is not possible to be performed in patients with ascites and in some areas TE and CAP measurements are made by technicians. ARFI technologies (pSWE and 2D-SWE) are included in standard ultrasound systems and fibrosis assessment (and others parameters) can be performed immediately after B-mode examination and can evaluate to the patients with ascites. International published guidelines regarding the practical values of all these techniques have been published [13, 14]. Barr et al. [84] showed the advantages and disadvantages of each method. The most recent guideline (from 2021) is the EASL Guideline for the use of the main non-invasive tests, with the important recommendations in this field [12].


4. Evaluation of inflammation

In patients with NAFLD, it is of crucial importance to differentiate between simple steatosis and steatohepatitis (NASH: non-alcoholic steatohepatitis). The best method for this is liver biopsy. However, having in mind the huge number of subjects with NAFLD (1/4 of the population in the developed countries), this invasive technique is not feasible in practice for all the patients. It has been demonstrated that using only biologic tests (such as aminotransferases or Cytokeratin 18) is not enough, thus new methods that accurately assess inflammation are necessary [85].

The newest high-end US machines include modules that evaluate the viscoelastic properties of the liver. This parameter is considered to be an expression of inflammation in the fatty liver, useful for the diagnosis of steatohepatitis (NASH).

Such a paper was published recently. Detection of steatosis, fibrosis and inflammation in 102 patients with NAFLD in comparison with liver biopsy was performed using a high-end US machine [86]. Attenuation coefficient(dB/cm/MHz) from attenuation imaging, liver stiffnessmeasurements, and shear wave dispersion slope(SWDS, [m/s]/kHz) from 2D-SWE were evaluated. The AUROC values for steatosis grades S1, S2 or S3, were 0.93, 0.88, and 0.83, respectively, while for lobular inflammatory activity (SWDS) the system detected inflammation grades 1, 2 and 3 with an AUROCs of 0.89, 0.85, and 0.78, respectively.

In a prospective study performed in a cohort of 120 consecutive adults who underwent liver biopsy for suspected NAFLD, Multiparametric US was used for liver assessment [87]. Three US parameters: dispersion slope[(m/s)/kHz], attenuation coefficient[dB/cm/MHz], and shear-wave speed(m/s), were evaluated with a 2D-SWE system, immediately before biopsy. This study has shown that dispersion slope identified lobular inflammation with an AUC of 0.95 (95% CI: 0.91, 0.10) for an inflammation grade ≥ A1 (mild), of 0.81 (95% CI: 0.72, 0.89) for an inflammation grade ≥ A2 (moderate), and of 0.85 (95% CI: 0.74, 0.97) for an inflammation grade A3 (marked). Considering the attenuation coefficient, it identified steatosis with an AUC of 0.88 (95% CI: 0.80, 0.97) for S ≥ 1 (mild), 0.86 (95% CI: 0.79, 0.93) for ≥S2 (moderate), and 0.79 (95% CI: 0.68, 0.89) for S3 (severe). Shear-wave speed identified fibrosis with an AUC of 0.79 (95% CI: 0.69, 0.88) for fibrosis stage F ≥ 1, of 0.88 (95% CI: 0.82, 0.94) for F ≥ 2, of 0.90 (95% CI: 0.84, 0.96) for F ≥ 3 and of 0.95 (95% CI: 0.91, 0.99) for F4 (cirrhosis). Probably the most important fact is that this combination of dispersion slope, attenuation coefficient, and shear-wave speed showed an AUC of 0.81 (95% CI: 0.71, 0.91) for the diagnosis of NASH.

Although, there are still many steps to go to reach an accurate software for the detection of inflammation using US waves, these early papers are encouraging for the noninvasive assessment of patients with NAFLD. All necessary information can be obtained using the Multiparametric Ultrasound (MPUS), and this is an ideal technique for NAFLD patients (quantification of fibrosis, steatosis and inflammation in less than 5 minutes) (Figure 9).

Figure 9.

Multiparameter ultrasound: 2D-SWE, Vi PLUS (viscosity index) and AttPLUS and SSpPLUS quantification.

In this moment, the main challenge in this field is to start the screening of the population at risk (MAFLD patients) for all the parameters of NAFLD [88]. Using simple biological tests [89] or maybe more sophisticated systems, such as ultrasound based or maybe MRI-based elastography, we can identify patients with advanced disease. Then intensive measures for such patients must be implemented.


5. Conclusion

Ultrasound methods are very useful for the evaluation of NAFLD patients. Identification of steatosis can be performed with standard ultrasound. Quantification of steatosis, fibrosis and inflammation can be assessed quickly with new high-tech ultrasound machines. Screening of patients at risk for the fatty liver with these modern tools is a challenge for the near future.


  1. 1. Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Translational Gastroenterology and Hepatology. 2020;5:16. DOI: 10.21037/tgh.2019.09.08
  2. 2. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. DOI: 10.1002/hep.28431
  3. 3. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123-133. DOI: 10.1002/hep.29466
  4. 4. Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World Journal of Gastroenterology. 2017;23(47):8263-8276. DOI: 10.3748/wjg.v23.i47.8263
  5. 5. Björkström K, Franzén S, Eliasson B, Miftaraj M, Gudbjörnsdottir S, Trolle-Lagerros Y, et al. Risk factors for severe liver disease in patients with type 2 diabetes. Clinical Gastroenterology and Hepatology. 2019;17(13):2769-2775.e4. DOI: 10.1016/j.cgh.2019.04.038
  6. 6. Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547-555. DOI: 10.1053/j.gastro.2014.11.039
  7. 7. Noureddin M, Vipani A, Bresee C, Todo T, Kim IK, Alkhouri N, et al. NASH leading cause of liver transplant in women: Updated analysis of indications for liver transplant and ethnic and gender variances. The American Journal of Gastroenterology. 2018;113(11):1649-1659. DOI: 10.1038/s41395-018-0088-6
  8. 8. Younossi ZM, Stepanova M, Ong J, Trimble G, AlQahtani S, Younossi I, et al. Nonalcoholic steatohepatitis is the Most rapidly increasing indication for liver transplantation in the United States. Clinical Gastroenterology and Hepatology. 2021;19(3):580-589.e5. DOI: 10.1016/j.cgh.2020.05.064
  9. 9. Eslam M, Sanyal AJ, George J. International consensus panel. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014.e1. DOI: 10.1053/j.gastro.2019.11.312
  10. 10. Lin S, Huang J, Wang M, Kumar R, Liu Y, Liu S, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver International. 2020;40(9):2082-2089. DOI: 10.1111/liv.14548
  11. 11. Sporea I, Popescu A, Dumitrașcu D, Brisc C, Nedelcu L, Trifan A, et al. Nonalcoholic fatty liver disease: Status quo. Journal of Gastrointestinal and Liver Diseases. 2018;27(4):439-448. DOI: 10.15403/jgld.2014.1121.274.quo
  12. 12. European Association for the Study of the Liver. Clinical Practice Guideline Panel; Chair: EASL Governing Board representative: Panel members. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. Journal of Hepatology. 2021;75(3):659-689. DOI: 10.1016/j.jhep.2021.05.025
  13. 13. Dietrich CF, Bamber J, Berzigotti A, Bota S, Cantisani V, et al. EFSUMB guidelines and recommendations on the clinical use of liver ultrasound Elastography, update 2017 (long version). Ultraschall in der Medizin-European Journal of Ultrasound. 2017;38(4):e16-e47. English. DOI: 10.1055/s-0043-103952 Erratum in: Ultraschall Med. 2017 Aug;38(4):e48
  14. 14. Ferraioli G, Wong VW, Castera L, Berzigotti A, Sporea I, Dietrich CF, et al. Liver ultrasound Elastography: An update to the world Federation for Ultrasound in medicine and biology guidelines and recommendations. Ultrasound in Medicine & Biology. 2018;44(12):2419-2440. DOI: 10.1016/j.ultrasmedbio.2018.07.008
  15. 15. Mathiesen UL, Franzén LE, Aselius H, Resjö M, Jacobsson L, Foberg U, et al. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Digestive and Liver Disease. 2002;34(7):516-522. DOI: 10.1016/s1590-8658(02)80111-6
  16. 16. Palmentieri B, de Sio I, La Mura V, Masarone M, Vecchione R, Bruno S, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Digestive and Liver Disease. 2006;38(7):485-489. DOI: 10.1016/j.dld.2006.03.021
  17. 17. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis. Hepatology. 2011;54(3):1082-1090. DOI: 10.1002/hep.24452
  18. 18. Gaitini D, Baruch Y, Ghersin E, Veitsman E, Kerner H, Shalem B, et al. Feasibility study of ultrasonic fatty liver biopsy: Texture vs. attenuation and backscatter. Ultrasound in Medicine & Biology. 2004;30(10):1321-1327. DOI: 10.1016/j.ultrasmedbio.2004.08.001
  19. 19. Mihăilescu DM, Gui V, Toma CI, Popescu A, Sporea I. Computer aided diagnosis method for steatosis rating in ultrasound images using random forests. Medical Ultrasonography. 2013;15(3):184-190. DOI: 10.11152/mu.2013.2066.153.dmm1vg2
  20. 20. Byra M, Styczynski G, Szmigielski C, Kalinowski P, Michałowski Ł, Paluszkiewicz R, et al. Transfer learning with deep convolutional neural network for liver steatosis assessment in ultrasound images. International Journal of Computer Assisted Radiology and Surgery. 2018;13(12):1895-1903. DOI: 10.1007/s11548-018-1843-2
  21. 21. Chan WK, Nik Mustapha NR, Mahadeva S. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology. 2014;29(7):1470-1476. DOI: 10.1111/jgh.12557
  22. 22. de Lédinghen V, Wong GL, Vergniol J, Chan HL, Hiriart JB, Chan AW, et al. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology. 2016;31(4):848-855. DOI: 10.1111/jgh.13219
  23. 23. Imajo K, Kessoku T, Honda Y, Tomeno W, Ogawa Y, Mawatari H, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient Elastography. Gastroenterology. 2016;150(3):626-637.e7. DOI: 10.1053/j.gastro.2015.11.048
  24. 24. Park CC, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, et al. Magnetic resonance Elastography vs transient Elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology. 2017;152(3):598-607.e2. DOI: 10.1053/j.gastro.2016.10.026
  25. 25. Naveau S, Voican CS, Lebrun A, Gaillard M, Lamouri K, Njiké-Nakseu M, et al. Controlled attenuation parameter for diagnosing steatosis in bariatric surgery candidates with suspected nonalcoholic fatty liver disease. European Journal of Gastroenterology & Hepatology. 2017;29(9):1022-1030. DOI: 10.1097/MEG.0000000000000919
  26. 26. Siddiqui MS, Vuppalanchi R, Van Natta ML, Hallinan E, Kowdley KV, Abdelmalek M, et al. NASH clinical research network. Vibration-controlled transient Elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology. 2019;17(1):156-163.e2. DOI: 10.1016/j.cgh.2018.04.043
  27. 27. Shalimar KR, Rout G, Kumar R, Yadav R, Das P, Aggarwal S, et al. Body mass index-based controlled attenuation parameter cut-offs for assessment of hepatic steatosis in non-alcoholic fatty liver disease. Indian Journal of Gastroenterology. 2020;39(1):32-41. DOI: 10.1007/s12664-019-00991-2
  28. 28. Oeda S, Takahashi H, Imajo K, Seko Y, Ogawa Y, Moriguchi M, et al. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan® M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: A multicenter prospective study. Journal of Gastroenterology. 2020;55(4):428-440. DOI: 10.1007/s00535-019-01635-0
  29. 29. Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717-1730. DOI: 10.1053/j.gastro.2019.01.042
  30. 30. Petroff D, Blank V, Newsome PN, Shalimar VCS, Thiele M, et al. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: An individual patient data meta-analysis. The Lancet Gastroenterology & Hepatology. 2021;6(3):185-198. DOI: 10.1016/S2468-1253(20)30357-5
  31. 31. Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Lédinghen V, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. Journal of Hepatology. 2017;66(5):1022-1030. DOI: 10.1016/j.jhep.2016.12.022
  32. 32. Kamali L, Adibi A, Ebrahimian S, Jafari F, Sharifi M. Diagnostic performance of ultrasonography in detecting fatty liver disease in comparison with Fibroscan in people suspected of fatty liver. Advanced Biomedical Research. 2019;8:69. DOI: 10.4103/abr.abr_114_19
  33. 33. Zenovia S, Stanciu C, Sfarti C, Singeap AM, Cojocariu C, Girleanu I, et al. Vibration-controlled transient Elastography and controlled attenuation parameter for the diagnosis of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Diagnostics (Basel). 2021;11(5):787. DOI: 10.3390/diagnostics11050787
  34. 34. Mikolasevic I, Domislovic V, Klapan M, Juric T, Lukic A, Krznaric-Zrnic I, et al. Accuracy of controlled attenuation parameter and liver stiffness measurement in patients with non-alcoholic fatty liver disease. Ultrasound in Medicine & Biology. 2021;47(3):428-437. DOI: 10.1016/j.ultrasmedbio.2020.11.015
  35. 35. Gu Q, Cen L, Lai J, Zhang Z, Pan J, Zhao F, et al. A meta-analysis on the diagnostic performance of magnetic resonance imaging and transient elastography in nonalcoholic fatty liver disease. European Journal of Clinical Investigation. 2021;51(2):e13446. DOI: 10.1111/eci.13446
  36. 36. Chan WK, Nik Mustapha NR, Mahadeva S, Wong VW, Cheng JY, Wong GL. Can the same controlled attenuation parameter cut-offs be used for M and XL probes for diagnosing hepatic steatosis? Journal of Gastroenterology and Hepatology. 2018;33(10):1787-1794. DOI: 10.1111/jgh.14150
  37. 37. Caussy C, Brissot J, Singh S, Bassirian S, Hernandez C, Bettencourt R, et al. Prospective, same-day, direct comparison of controlled attenuation parameter with the M vs the XL probe in patients with nonalcoholic fatty liver disease, using magnetic resonance imaging-proton density fat fraction as the standard. Clinical Gastroenterology and Hepatology. 2020;18(8):1842-1850.e6. DOI: 10.1016/j.cgh.2019.11.060
  38. 38. Fujiwara Y, Kuroda H, Abe T, Ishida K, Oguri T, Noguchi S, et al. The B-mode image-guided ultrasound attenuation parameter accurately detects hepatic steatosis in chronic liver disease. Ultrasound in Medicine & Biology. 2018;44(11):2223-2232. DOI: 10.1016/j.ultrasmedbio.2018.06.017
  39. 39. Ferraioli G, Maiocchi L, Savietto G, Tinelli C, Nichetti M, Rondanelli M, et al. Performance of the attenuation imaging Technology in the Detection of liver steatosis. Journal of Ultrasound in Medicine. 2021;40(7):1325-1332. DOI: 10.1002/jum.15512
  40. 40. Bae JS, Lee DH, Lee JY, Kim H, Yu SJ, Lee JH, et al. Assessment of hepatic steatosis by using attenuation imaging: A quantitative, easy-to-perform ultrasound technique. European Radiology. 2019;29(12):6499-6507. DOI: 10.1007/s00330-019-06272-y
  41. 41. Jeon SK, Lee JM, Joo I, Yoon JH, Lee DH, Lee JY, et al. Prospective evaluation of hepatic steatosis using ultrasound attenuation imaging in patients with chronic liver disease with magnetic resonance imaging proton density fat fraction as the reference standard. Ultrasound in Medicine & Biology. 2019;45(6):1407-1416. DOI: 10.1016/j.ultrasmedbio.2019.02.008
  42. 42. Tamaki N, Koizumi Y, Hirooka M, Yada N, Takada H, Nakashima O, et al. Novel quantitative assessment system of liver steatosis using a newly developed attenuation measurement method. Hepatology Research. 2018;48(10):821-828. DOI: 10.1111/hepr.13179
  43. 43. Dioguardi Burgio M, Imbault M, Ronot M, Faccinetto A, Van Beers BE, Rautou PE, et al. Ultrasonic adaptive sound speed estimation for the diagnosis and quantification of hepatic steatosis: A pilot study. Ultraschall in der Medizin-European Journal of Ultrasound. 2019;40(6):722-733. English. DOI: 10.1055/a-0660-9465
  44. 44. Popa A, Bende F, Șirli R, Popescu A, Bâldea V, Lupușoru R, et al. Quantification of liver fibrosis, steatosis, and viscosity using multiparametric ultrasound in patients with non-alcoholic liver disease: A "real-life" cohort study. Diagnostics (Basel). 2021;11(5):783. DOI: 10.3390/diagnostics11050783
  45. 45. Jeon SK, Lee JM, Joo I, Park SJ. Quantitative ultrasound radiofrequency data analysis for the assessment of hepatic steatosis in nonalcoholic fatty liver disease using magnetic resonance imaging proton density fat fraction as the reference standard. Korean Journal of Radiology. 2021;22(7):1077-1086. DOI: 10.3348/kjr.2020.1262
  46. 46. Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547-1554. DOI: 10.1002/hep.27368
  47. 47. Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. Journal of Hepatology. 2017;67(6):1265-1273. DOI: 10.1016/j.jhep.2017.07.027
  48. 48. Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51(2):454-462. DOI: 10.1002/hep.23312
  49. 49. Cassinotto C, Boursier J, de Lédinghen V, Lebigot J, Lapuyade B, et al. Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. Hepatology. 2016;63(6):1817-1827. DOI: 10.1002/hep.28394
  50. 50. Petta S, Wong VW, Cammà C, Hiriart JB, Wong GL, Marra F, et al. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. Hepatology. 2017;65(4):1145-1155. DOI: 10.1002/hep.28843
  51. 51. Yoneda M et al. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut. 2007;56:1330-1331. DOI: 10.1136/gut.2007.126417
  52. 52. Gaia S, Carenzi S, Barilli AL, Bugianesi E, Smedile A, Brunello F, et al. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. Journal of Hepatology. 2011;54(1):64-71. DOI: 10.1016/j.jhep.2010.06.022
  53. 53. Kumar R, Rastogi A, Sharma MK, Bhatia V, Tyagi P, Sharma P, et al. Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease: Diagnostic performance and clinicopathological correlation. Digestive Diseases and Sciences. 2013;58(1):265-274. DOI: 10.1007/s10620-012-2306-1
  54. 54. Lupsor M, Badea R, Stefanescu H, Grigorescu M, Serban A, Radu C, et al. Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis. Journal of Gastrointestinal and Liver Diseases. 2010;19(1):53-60
  55. 55. Petta S, Di Marco V, Cammà C, Butera G, Cabibi D, Craxì A. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: The effects of body mass index. Alimentary Pharmacology & Therapeutics. 2011;33(12):1350-1360. DOI: 10.1111/j.1365-2036.2011.04668.x
  56. 56. Ratziu V, Bugianesi E, Dixon J, Fassio E, Ekstedt M, Charlotte F, et al. Histological progression of non-alcoholic fatty liver disease: A critical reassessment based on liver sampling variability. Alimentary Pharmacology & Therapeutics. 2007;26(6):821-830. DOI: 10.1111/j.1365-2036.2007.03425.x
  57. 57. Yoneda M, Yoneda M, Mawatari H, Fujita K, Endo H, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Digestive and Liver Disease. 2008;40(5):371-378. DOI: 10.1016/j.dld.2007.10.019
  58. 58. Nobili V, Vizzutti F, Arena U, Abraldes JG, Marra F, Pietrobattista A, et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology. 2008;48(2):442-448. DOI: 10.1002/hep.22376
  59. 59. Wong VW, Vergniol J, Wong GL, Foucher J, Chan AW, Chermak F, et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. The American Journal of Gastroenterology. 2012;107:1862-1871. DOI: 10.1038/ajg.2012.331
  60. 60. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Annals of Medicine. 2011;43(8):617-649. DOI: 10.3109/07853890.2010.518623
  61. 61. Yoneda M, Suzuki K, Kato S, Fujita K, Nozaki Y, Hosono K, et al. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology. 2010;256(2):640-647. DOI: 10.1148/radiol.10091662
  62. 62. Mahadeva S, Mahfudz AS, Vijayanathan A, Goh KL, Kulenthran A, Cheah PL. Performance of transient elastography (TE) and factors associated with discordance in non-alcoholic fatty liver disease. Journal of Digestive Diseases. 2013;14(11):604-610. DOI: 10.1111/1751-2980.12088
  63. 63. Pathik P, Ravindra S, Ajay C, Prasad B, Jatin P, Prabha S. Fibroscan versus simple noninvasive screening tools in predicting fibrosis in high-risk nonalcoholic fatty liver disease patients from Western India. Annals of Gastroenterology. 2015;28(2):281-286
  64. 64. Seki K, Shima T, Oya H, Mitsumoto Y, Mizuno M, Okanoue T. Assessment of transient elastography in Japanese patients with non-alcoholic fatty liver disease. Hepatology Research. 2017;47(9):882-889. DOI: 10.1111/hepr.12829
  65. 65. Lee MS, Bae JM, Joo SK, Woo H, Lee DH, Jung YJ, et al. Prospective comparison among transient elastography, supersonic shear imaging, and ARFI imaging for predicting fibrosis in nonalcoholic fatty liver disease. PLoS One. 2017;12(11):e0188321. DOI: 10.1371/journal.pone.0188321 Erratum in: PLoS One. 2018 Jun 26;13(6):e0200055
  66. 66. Hsu C, Caussy C, Imajo K, Chen J, Singh S, Kaulback K, et al. Magnetic resonance vs transient Elastography analysis of patients with nonalcoholic fatty liver disease: A systematic review and pooled analysis of individual participants. Clinical Gastroenterology and Hepatology. 2019;17(4):630-637.e8. DOI: 10.1016/j.cgh.2018.05.059
  67. 67. Attia D, Bantel H, Lenzen H, Manns MP, Gebel MJ, Potthoff A. Liver stiffness measurement using acoustic radiation force impulse elastography in overweight and obese patients. Alimentary Pharmacology & Therapeutics. 2016;44(4):366-379. DOI: 10.1111/apt.13710
  68. 68. Myers RP, Pomier-Layrargues G, Kirsch R, Pollett A, Duarte-Rojo A, Wong D, et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology. 2012;55(1):199-208. DOI: 10.1002/hep.24624
  69. 69. Myers RP, Elkashab M, Ma M, Crotty P, Pomier-Layrargues G. Transient elastography for the noninvasive assessment of liver fibrosis: A multicentre Canadian study. Canadian Journal of Gastroenterology. 2010;24(11):661-670. DOI: 10.1155/2010/153986
  70. 70. Furlan A, Tublin ME, Yu L, Chopra KB, Lippello A, Behari J. Comparison of 2D shear wave Elastography, transient Elastography, and MR Elastography for the diagnosis of fibrosis in patients with nonalcoholic fatty liver disease. AJR. American Journal of Roentgenology. 2020 Jan;214(1):W20-W26. DOI: 10.2214/AJR.19.21267
  71. 71. Leong WL, Lai LL, Nik Mustapha NR, Vijayananthan A, Rahmat K, Mahadeva S, et al. Comparing point shear wave elastography (ElastPQ) and transient elastography for diagnosis of fibrosis stage in non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology. 2020;35(1):135-141. DOI: 10.1111/jgh.14782
  72. 72. Imajo K, Honda Y, Kobayashi T, Nagai K, Ozaki A, Iwaki M, et al. Direct comparison of US and MR Elastography for staging liver fibrosis in patients with nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology. 2020;S1542-3565(20):31673-31676. DOI: 10.1016/j.cgh.2020.12.016
  73. 73. Fierbinteanu Braticevici C, Sporea I, Panaitescu E, Tribus L. Value of acoustic radiation force impulse imaging elastography for non-invasive evaluation of patients with nonalcoholic fatty liver disease. Ultrasound in Medicine & Biology. 2013;39(11):1942-1950. DOI: 10.1016/j.ultrasmedbio.2013.04.019
  74. 74. Cassinotto C, Lapuyade B, Aït-Ali A, Vergniol J, Gaye D, Foucher J, et al. Liver fibrosis: Noninvasive assessment with acoustic radiation force impulse elastography--comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease. Radiology. 2013;269(1):283-292. DOI: 10.1148/radiol.13122208
  75. 75. Friedrich-Rust M, Romen D, Vermehren J, Kriener S, Sadet D, Herrmann E, et al. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. European Journal of Radiology. 2012;81(3):e325-ee31. DOI: 10.1016/j.ejrad.2011.10.029
  76. 76. Osaki A, Kubota T, Suda T, Igarashi M, Nagasaki K, Tsuchiya A, et al. Shear wave velocity is a useful marker for managing nonalcoholic steatohepatitis. World Journal of Gastroenterology: WJG. 2010;16(23):2918
  77. 77. Palmeri ML, Wang MH, Rouze NC, Abdelmalek MF, Guy CD, Moser B, et al. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. Journal of Hepatology. 2011;55(3):666-672. DOI: 10.1016/j.jhep.2010.12.019
  78. 78. Cui J, Heba E, Hernandez C, Haufe W, Hooker J, Andre MP, et al. Magnetic resonance elastography is superior to acoustic radiation force impulse for the diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: A prospective study. Hepatology. 2016;63(2):453-461. DOI: 10.1002/hep.28337
  79. 79. Li Y, Dong C. Diagnostic value of acoustic radiation force impluse imaging and APRI ratio index for quantitative for evaluating the degree of liver fibrosis in non-alcoholic fatty liver disease patients. Chinese Journal of Ultrasound in Medicine. 2017;(12):544-548
  80. 80. Sharpton SR, Tamaki N, Bettencourt R, Madamba E, Jung J, Liu A, et al. Diagnostic accuracy of two-dimensional shear wave elastography and transient elastography in nonalcoholic fatty liver disease. Therapeutic Advances in Gastroenterology. 2021;14:17562848211050436. DOI: 10.1177/17562848211050436. PMID: 34646360; PMCID: PMC8504217
  81. 81. Herrmann E, de Lédinghen V, Cassinotto C, Chu WC, Leung VY, Ferraioli G, et al. Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: An individual patient data-based meta-analysis. Hepatology. 2018;67(1):260-272. DOI: 10.1002/hep.29179
  82. 82. Takeuchi H, Sugimoto K, Oshiro H, Iwatsuka K, Kono S, Yoshimasu Y, et al. Liver fibrosis: Noninvasive assessment using supersonic shear imaging and FIB4 index in patients with non-alcoholic fatty liver disease. Journal of Medical Ultrasonics (2001). 2018;45(2):243-249. DOI: 10.1007/s10396-017-0840-3
  83. 83. Jamialahmadi T, Nematy M, Jangjoo A, Goshayeshi L, Rezvani R, Ghaffarzadegan K, et al. Measurement of liver stiffness with 2D-shear wave Elastography (2D-SWE) in bariatric surgery candidates reveals acceptable diagnostic yield compared to liver biopsy. Obesity Surgery. 2019;29(8):2585-2592. DOI: 10.1007/s11695-019-03889-2
  84. 84. Barr RG, Wilson SR, Rubens D, Garcia-Tsao G, Ferraioli G. Update to the Society of Radiologists in ultrasound liver Elastography consensus statement. Radiology. 2020;296(2):263-274. DOI: 10.1148/radiol.2020192437
  85. 85. Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(5):1264-1281.e4. DOI: 10.1053/j.gastro.2018.12.036
  86. 86. Lee DH, Cho EJ, Bae JS, Lee JY, Yu SJ, Kim H, et al. Accuracy of two-dimensional shear wave Elastography and attenuation imaging for evaluation of patients with nonalcoholic steatohepatitis. Clinical Gastroenterology and Hepatology. 2021;19(4):797-805.e7. DOI: 10.1016/j.cgh.2020.05.034
  87. 87. Sugimoto K, Moriyasu F, Oshiro H, Takeuchi H, Abe M, Yoshimasu Y, et al. The role of multiparametric US of the liver for the evaluation of nonalcoholic steatohepatitis. Radiology. 2020;296(3):532-540. DOI: 10.1148/radiol.2020192665
  88. 88. Sporea I. To screen or not to screen for NAFLD? Medical Ultrasonography. 2021;23(2):133-134. DOI: 10.11152/mu-3251
  89. 89. Pandyarajan V, Gish RG, Alkhouri N, Noureddin M. Screening for nonalcoholic fatty liver disease in the primary care clinic. Gastroenterology & Hepatology (NY). 2019;15(7):357-365

Written By

Ioan Sporea, Raluca Lupușoru and Roxana Șirli

Submitted: December 3rd, 2021 Reviewed: December 22nd, 2021 Published: March 1st, 2022